Alpha Tau advances multi-indication Alpha DaRT with REGAIN results and Tolmar deal
Aug 10, 2026, 4:06 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Positive interim data (REGAIN) and FDA clearance reduce regulatory risk; Tolmar deal introduces meaningful US commercialization leverage and milestones, expanding addressable market. While the company is still loss-making, the scale of milestones and manufacturing investments lowers near-term dilution risk and could trigger multiple expansion in multiple data-readouts toward year-end.
AI summary
What happened, with direct paths to the underlying reporting
Alpha Tau reported groundbreaking interim REGAIN results in recurrent glioblastoma (100% local control, 67% complete responses) and FDA clearance to complete enrollment with two additional U.S. centers. It also unveiled a strategic Tolmar collaboration for US prostate cancer, including a $20 million equity investment and up to $161.5 million in milestones, signaling a broader commercial path alongside new pancreatic cancer data and a fully enrolled U.S. cSCC trial.
REGAIN interim GBM: 100% local control; 67% complete responses.
FDA clears enrollment; adds two U.S. sites for REGAIN.
Tolmar collab to commercialize Alpha DaRT for US prostate cancer.
Tolmar deal: $20m equity at 25% premium; $15m for U.S. manufacturing.
Up to $161.5m milestones; 60% of net sales payable to Alpha.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Recent updates from the REGAIN study indicate positive responses in glioblastoma treatments, with two patients achieving complete tumor disappearance. DRTS has shown remarkable st…
